Media coverage about iCo Therapeutics (OTCMKTS:ICOTF) has trended somewhat positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. iCo Therapeutics earned a media sentiment score of 1.18 on their scale. InfoTrie also assigned news stories about the biotechnology company an news buzz score of 10 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock’s share price in the immediate future.
OTCMKTS ICOTF remained flat at $$0.07 on Friday. The company had a trading volume of 9,800 shares, compared to its average volume of 1,327. The company has a 50-day moving average price of $0.05. iCo Therapeutics has a 12 month low of $0.03 and a 12 month high of $0.13.
iCo Therapeutics Company Profile
iCo Therapeutics Inc, a biotechnology company, focuses on the identification, development, and commercialization of drug candidates to treat sight and life threatening diseases. Its in-licensed product candidates include iCo-008, a human monoclonal antibody, which is in Phase II clinical trial to treat sight threatening ocular allergies and various systemic disease indications; and Oral AmpB Delivery System that is in pre-clinical stage used for the treatment of systemic fungal infections.
See Also: Net Asset Value
Receive News & Ratings for iCo Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for iCo Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.